Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
[en] BACKGROUND: In animal models of breast cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroduction of letrozole. We therefore hypothesised that extended intermittent use of adjuvant letrozole would improve breast cancer outcome compared with continuous use of letrozole in postmenopausal women. METHODS: We did the multicentre, open-label, randomised, parallel, phase 3 SOLE trial in 240 centres (academic, primary, secondary, and tertiary care centres) in 22 countries. We enrolled postmenopausal women of any age with hormone receptor-positive, lymph node-positive, and operable breast cancer for which they had undergone local treatment (surgery with or without radiotherapy) and had completed 4-6 years of adjuvant endocrine therapy. They had to be clinically free of breast cancer at enrolment and without evidence of recurrent disease at any time before randomisation. We randomly assigned women (1:1) to treatment groups of either continuous use of letrozole (2.5 mg/day orally for 5 years) or intermittent use of letrozole (2.5 mg/day orally for 9 months followed by a 3-month break in years 1-4 and then 2.5 mg/day during all 12 months of year 5). Randomisation was done by principal investigators or designee at respective centres through the internet-based system of the International Breast Cancer Study Group, was stratified by type of previous endocrine therapy (aromatase inhibitors only vs selective oestrogen receptor modulators only vs both therapies), and used permuted block sizes of four and institutional balancing. No one was masked to treatment assignment. The primary endpoint was disease-free survival, analysed by the intention-to-treat principle using a stratified log-rank test. All patients in the intention-to-treat population who initiated protocol treatment during their period of trial participation were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT00553410, and EudraCT, number 2007-001370-88; and long-term follow-up of patients is ongoing. FINDINGS: Between Dec 5, 2007, and Oct 8, 2012, 4884 women were enrolled and randomised after exclusion of patients at a non-adherent centre, found to have inadequate documentation of informed consent, immediately withdrew consent, or randomly assigned to intervention groups in error. 4851 women comprised the intention-to-treat population that compared extended intermittent letrozole use (n=2425) with continuous letrozole use (n=2426). After a median follow-up of 60 months (IQR 53-72), disease-free survival was 85.8% (95% CI 84.2-87.2) in the intermittent letrozole group compared with 87.5% (86.0-88.8) in the continuous letrozole group (hazard ratio 1.08, 95% CI 0.93-1.26; p=0.31). Adverse events were reported as expected and were similar between the two groups. The most common grade 3-5 adverse events were hypertension (584 [24%] of 2417 in the intermittent letrozole group vs 517 [21%] of 2411 in the continuous letrozole group) and arthralgia (136 [6%] vs 151 [6%]). 54 patients (24 [1%] in the intermittent letrozole group and 30 [1%] in the continuous letrozole group) had grade 3-5 CNS cerebrovascular ischaemia, 16 (nine [<1%] vs seven [<1%]) had grade 3-5 CNS haemorrhage, and 40 (19 [1%] vs 21 [1%]) had grade 3-5 cardiac ischaemia. In total, 23 (<1%) of 4851 patients died while on trial treatment (13 [<1%] of 2417 patients in the intermittent letrozole group vs ten [<1%] of 2411 in the continuous letrozole group). INTERPRETATION: In postmenopausal women with hormone receptor-positive breast cancer, extended use of intermittent letrozole did not improve disease-free survival compared with continuous use of letrozole. An alternative schedule of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might be feasible and the results of the SOLE trial support the safety of temporary treatment breaks in selected patients who might require them. FUNDING: Novartis and the International Breast Cancer Study Group.
Disciplines :
Oncology
Author, co-author :
Colleoni, Marco
Luo, Weixiu
Karlsson, Per
Chirgwin, Jacquie H.
Aebi, Stefan
Jerusalem, Guy ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Publication date :
2018
Journal title :
The Lancet Oncology
ISSN :
1470-2045
eISSN :
1474-5488
Publisher :
The Lancet Publishing Group, United Kingdom
Volume :
19
Issue :
1
Pages :
127-138
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2018 Elsevier Ltd. All rights reserved.
Goss, PE, Ingle, JN, Martino, S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003), 1793–1802.
Jin, H, Tu, D, Zhao, N, Shepherd, LE, Goss, PE, Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 30 (2012), 718–721.
Goss, PE, Ingle, JN, Pritchard, KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375 (2016), 209–219.
Mamounas EP, Bandos H, Lembersky BC, et al. A randomized, double-blinded, placebo-controlled clinical trial to evaluate extended adjuvant endocrine therapy (5 years of letrozole) in postmenopausal women with hormone-receptor positive breast cancer who have completed previous adjuvant endocrine therapy: initial results of NRG oncology/NSABP B-42. 2016 San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 6–10, 2016. S1-05 (abstr).
Curigliano, G, Burstein, HJ, Winer, EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017. Ann Oncol 28 (2017), 1700–1712.
Sabnis, GJ, Macedo, LF, Goloubeva, O, Schayowitz, A, Brodie, AM, Stopping treatment can reverse acquired resistance to letrozole. Cancer Res 68 (2008), 4518–4524.
Song, RX, Mor, G, Naftolin, F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93 (2001), 1714–1723.
Lewis, JS, Osipo, C, Meeke, K, Jordan, VC, Estrogen-induced apoptosis in breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 94 (2005), 131–141.
Yao, K, Lee, ES, Bentrem, DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6 (2000), 2028–2036.
Stanton, AL, Bernaards, CA, Ganz, PA, The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst 97 (2005), 448–456.
Bernhard, J, Hürny, C, Coates, AS, et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol 8 (1997), 825–835.
Bernhard, J, Sullivan, M, Huerny, C, Coates, AS, Rudenstam, CM, Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84 (2001), 1156–1165.
Hudis, CA, Barlow, WE, Costantino, JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25 (2007), 2127–2132.
Goss, PE, Ingle, JN, Martino, S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005), 1262–1271.
Iveson, TJ, Smith, IE, Ahern, J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 77 (1993), 324–331.
Lonning, PE, Taylor, PD, Anker, G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67 (2001), 111–116.
Jordan, VC, The 38th David A Karnofsky lecture: the paradoxical actions of estrogen in breast cancer—survival or death?. J Clin Oncol 26 (2008), 3073–3082.
Yue, W, Zhou, D, Chen, S, Brodie, A, A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54 (1994), 5092–5095.
Sabnis, GJ, Jelovac, D, Long, B, Brodie, A, The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65 (2005), 3903–3910.
Davies, C, Pan, H, Godwin, J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381 (2013), 805–816.
Dunn, C, Keam, SJ, Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Pharmacoeconomics 24 (2006), 495–517.
Nattinger, AB, Pezzin, LE, McGinley, EL, Charlson, JA, Yen, TW, Neuner, JM, Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations. Springerplus, 4, 2015, 54.
Yen, TW, Czypinski, LK, Sparapani, RA, et al. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer 117 (2011), 398–405.